BUSINESS Dr. Lal PathLabs announces ₹4 per share dividend and acquisition of Shahbazkers Diagnostic Centre 3:37 PM IST
BUSINESS Dr. Lal PathLabs receives NCLT approval for dissolution of Suburban Diagnostics Mar 10, 2026
Dr. Lal PathLabs becomes first in India to adopt AI-based module for cancer lymph node metastasis detection Aug 20, 2025
Dr. Lal PathLabs shares jump 8% from day low as Q4 revenue rises 10.48% YoY to 602.6 crore Apr 25, 2025
Dr. Lal PathLabs Q3 FY25 Results: Revenue rises 11% YoY to Rs 622 crore, Net Profit up 19% YoY Jan 30, 2025
Dr. Lal Pathlabs stock surges nearly 3% as CLSA upgrade to “Outperform” rating with target price of Rs 3,240 Jan 23, 2025